All In Biotech

Drug Trial Radar · NCT05142514

Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)

A Phase IIb Study to Evaluate Safety and Immunogenicity of a Recombinant Protein RBD Fusion Dimer Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 629 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

629

Actual

Start

Nov 11, 2021

Primary completion

May 6, 2022

Study completion May 6, 2022

Sponsor

Lead sponsor
Hipra Scientific, S.L.UIndustry
Sponsor type
Industry
Collaborators
Laboratorios Hipra, S.A.; National Institute of Hygiene and Epidemiology, Vietnam
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam

Conditions

  • SARS-CoV-2 Infection

Interventions

  • COVID-19 Vaccine HIPRABiological

    Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart

  • Cominarty (Pfizer-BioNtech)Biological

    Subjects will receive 2 injections of Cominarty administered 21 days apart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 7 days
  2. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 28 days
  3. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 7 days
  4. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 30 weeks
  5. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 30 weeks
  6. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 30 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Hygiene and Epidemiology

    Hanoi, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.